Health Care

German stocks inch up on Fresenius boost, but rising yields and EU policy shifts keep investors cautious; key sector insights and risks revealed.

How value‑based care, telehealth, and AI diagnostics are reshaping U.S. hospitals’ margins, savings, and patient outcomes—insights for executives seeking ROI and quality gains.

Fisher & Paykel Healthcare sells 13 hectares to fund a new South Auckland hospital, boosting community care while keeping space for future medical‑tech growth.

German healthcare faces shifting reimbursements, workforce shortages, and tech costs—discover strategies to boost quality, cut spend, and thrive in volatility.

Genmab’s Rina‑S ADC shows 45% ORR and 12‑month DoR in platinum‑resistant ovarian cancer, even low‑FR‑α cases, offering a new, value‑based treatment option.

Quest Diagnostics’ latest strategy: expand high‑throughput labs, boost automation, strengthen data security—aiming for margin growth while navigating payer and regulatory pressure.

IQVIA Holdings’ strategy to grow high‑margin generics, oncology and peptide therapeutics, backed by a strong cash position, fuels optimistic earnings and shareholder value growth.

Swiss market index steadies on falling oil, lower bond yields, and muted US rates—AB, Sika, Julius Baer gain, Straumann dips; firms eye modest equity gains and commodity‑linked costs.

CEO insider trades show United Therapeutics’ confidence in rising EBITDA, amid value‑based contracts, supply‑chain stress, and a strong 18.2% margin outlook.

Quest Diagnostics (DGX) reports a $135 phantom stock grant to board member Timothy C. Wentworth, a key move in its non‑equity incentive strategy to align leadership with shareholder value.